The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against 8- cell Maturation Antigen (BCMA). The invention also provides for use of the chimeric antigen receptor in adoptive T cell therapies for B cell related conditions.L'invention concerne des compositions améliorées destinées à des thérapies adoptives par lymphocytes T pour des affections liées aux cellules B.